The proportion of patients with relatives who had BC was highest in the TNBC group (22.2%), followed by the Luminal A (19.3%) and Luminal B (12.5%) groups, with the lowest in the HER2-enriched group (6.7%). Here, ERBB2 is linked to breast cancer.